Ovarian Cancer

Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.

There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.

As a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options.

In her Introduction to the special edition of CONQUER titled Understanding Biomarkers & Molecular Testing, Lillie D. Shockney, RN, BS, MAS, ONN-CG, briefly explains what biomarkers are, why they are important, and what you should know about them.  

Dr. Julian Schink, GYN Oncology Chief of Cancer Treatment Centers of America, provides screening tips and recommendations for these 2 most common gynecologic cancers.

In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.

Ovarian cancer ranks fifth in cancer-related deaths in women, accounting for more deaths than any other cancer of the female reproductive system.

In 1997 I was 27, happy, free, and traveling the world as a flight attendant. Newly married and ready to have a baby, I felt strong and invincible. My future was unfolding just as I expected it to. Until the symptoms appeared ever so subtly.